CJL

Catherine Laufmann InspectorProfile

$795.00

This InspectorProfile is a report of relevant audit-related information on Catherine Laufmann, a U.S. Food & Drug Administration investigator who primarily conducts inspections in the area of Medical Devices & Rad Health.

Product Description

This InspectorProfile report is updated through and lists Catherine Laufmann's 301 inspections in 33 countries: United States, Germany, Norway, Italy, France, United Kingdom, Switzerland, Netherlands, Canada, China, Taiwan, Ireland, Sweden, Japan, Spain, Czech Republic, Dominican Republic (the), Denmark, Mexico, Slovakia, Singapore, Israel, Australia, Korea (the Republic of), Hong Kong SAR, Belgium, Greece, Poland, Philippines, Croatia, Malaysia, Estonia, and Austria.

FDA audits are stressful. Whether you are issued a 483 depends largely on your compliance with GxP and predicate rules; but it can also depend on the Agency's current focus and the tendencies of your specific investigator(s). FDAzilla has curated Catherine Laufmann's inspection information so that you can mitigate investigator-related risks.

Below is an example of what a FDAzilla InspectorProfile report contains; This is not the actual data for Catherine Laufmann.

Example Report

Catherine Laufmann FDA InspectorProfile Overview Example
Catherine Laufmann FDA InspectorProfile Metrics Example
Catherine Laufmann FDA InspectorProfile Citations Example
Catherine Laufmann FDA InspectorProfile Inspections List
Add To Cart21 of Laufmann 483s in stock

Product details

  • Catherine Laufmann's metrics:
    • 483 issue rate, total inspections, total 483s
    • Most common citations (based on CFR), CFR description, and citation frequency
    • Total inspections, total 483s
    • Longest / shortest inspection in duration - all time, last year
    • Total warning letters
  • Inspection details for each inspection (since 2000) Catherine Laufmann has conducted including:

Note: The EIR and 483 documents are sold separately.

Add To Cart21 of Catherine's 483s Available Now.